HSP90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy

Theranostics

Volumn 6, Issue 9, 2016, Pages 1324-1335

  Lin, Tzu Yin ^a   Guo, Wenchang ^b   Long, Qilai ^c   Ma, Aihong ^d   Liu, Qiangqiang ^d   Zhang, Hongyong ^a   Huang, Yee ^d   Chandrasekaran, Siddarth ^d   Pan, Chongxian ^a,e   Lam, Kit S ^a,d   Li, Yuanpei ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Combination therapy; Hsp90 inhibitor; Nano theranostics; Photo therapy; Prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; NITROGEN; PORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; TANESPIMYCIN; UREA; ANTINEOPLASTIC AGENT; DRUG CARRIER; HEAT SHOCK PROTEIN 90; NANOPARTICLE; PORPHYRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOCOMPATIBILITY; BLOOD CELL COUNT; CANCER THERAPY; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MOUSE; MTT ASSAY; NANOENCAPSULATION; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTHERMAL THERAPY; PROSTATE CANCER; THERANOSTIC NANOMEDICINE; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HEAT; HUMAN; MALE; METABOLISM; PHOTOCHEMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; THERMOTHERAPY; TREATMENT OUTCOME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; HETEROGRAFTS; HOT TEMPERATURE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; MALE; MICE; NANOPARTICLES; PHOTOCHEMOTHERAPY; PORPHYRINS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; THERANOSTIC NANOMEDICINE; TREATMENT OUTCOME;

EID: 84991619016     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.14882     Document Type: Article

References (30)

1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011; 61: 250-81
2. Ferrario A, Gomer CJ. Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer letters. 2010; 289: 188-94
3. Savellano MD, Owusu-Brackett N, Son J, Ganga T, Leung NL, Savellano DH. Photodynamic tumor eradication with a novel targetable photosensitizer: strong vascular effects and dependence on treatment repetition versus potentiation. Photochem Photobiol. 2013; 89: 687-97
4. Lim CK, Heo J, Shin S, Jeong K, Seo YH, Jang WD, et al. Nanophotosensitizers toward advanced photodynamic therapy of Cancer. Cancer Lett. 2012
5. Bugaj AM. Targeted photodynamic therapy-a promising strategy of tumor treatment. Photochem Photobiol Sci. 2011; 10: 1097-109
6. Zhao B, He YY. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther. 2010; 10: 1797-809
7. Derycke AS, de Witte PA. Liposomes for photodynamic therapy. Adv Drug Deliv Rev. 2004; 56: 17-30
8. Chen B, Pogue BW, Zhou X, O'Hara JA, Solban N, Demidenko E, et al. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res. 2005; 11: 720-7
9. Ferrario A, Rucker N, Wong S, Luna M, Gomer CJ. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res. 2007; 67: 4989-95
10. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003; 425: 407-10
11. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005; 65: 10006-15
12. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res. 2007; 13: 1625-9
13. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Seminars in oncology. 2003; 30: 709-16
14. Huynh E, Zheng G. Engineering multifunctional nanoparticles: all-in-one versus one-for-all. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology. 2013; 5: 250-65
15. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater. 2011; 10: 324-32
16. Li Y, Lin TY, Luo Y, Liu Q, Xiao W, Guo W, et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun. 2014; 5: 4712
17. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009; 30: 6006-16
18. Li Y, Xiao K, Luo J, Lee J, Pan S, Lam KS. A novel size-tunable nanocarrier system for targeted anticancer drug delivery. Journal of Controlled Release. 2010; 144: 314-23
19. Li Y, Xiao K, Luo J, Xiao W, Lee JS, Gonik AM, et al. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials. 2011; 32: 6633-45
20. Li Y, Xiao W, Xiao K, Berti L, Luo J, Tseng HP, et al. Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols. Angew Chem Int Ed Engl. 2012; 51: 2864-9
21. Rong P, Yang K, Srivastan A, Kiesewetter DO, Yue X, Wang F, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014; 4: 229-39
22. Ng KK, Lovell JF, Vedadi A, Hajian T, Zheng G. Self-assembled porphyrin nanodiscs with structure-dependent activation for phototherapy and photodiagnostic applications. ACS nano. 2013; 7: 3484-90
23. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews. 2006; 58: 621-81
24. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research. 2010; 70: 440-6
25. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene. 1997; 15: 2705-16
26. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN, Jr., et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014; 33: 4521-30
27. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011; 32: 3435-46
28. Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell death & disease. 2011; 2: e156
29. de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 12337-42
30. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther. 2003; 2: 131-8